Abisati

Abisati is a San Diego-based biotechnology company specializing in the discovery and development of novel small molecule therapeutics targeting deubiquitinating enzymes (DUBs). The company's primary research focus is on Ubiquitin Specific Peptidase 7 (USP7), a critical enzyme that regulates the stability of proteins involved in tumor suppression and immune system modulation. By leveraging its proprietary discovery platform, Abisati aims to develop highly selective inhibitors that can restore natural cellular pathways to treat various cancers and autoimmune disorders. Currently in the pre-clinical stage, the company is advancing its lead programs toward IND-enablement while expanding its expertise in the ubiquitin-proteasome system. Abisati was founded by industry veterans with significant experience in protein degradation and deubiquitination pathways.